Displaying 105 (all) recruiting clinical trials.
-
A Phase 3 Randomized Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (UpRi) as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT).
You can participate in this study if you are diagnosed with Platinum-Sensitive Recurrent Ovarian Cancer. In this study we will evaluate the study drug (Upifitamab ... -
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence.
You can participate in this study if you are diagnosed with ER+, HER2- Early Breast Cancer (Stages I-III) with an Increased Risk of Recurrence. And ... -
A Phase 3 Open-Label Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Push Compared with Intravenous Amivantamab or Subcutaneous Amivantamab Administered via On Body Delivery System in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy.
You can participate in this study if you are diagnosed with advanced lung cancer. The purpose of this study is to know the efficacy and ... -
Impact Of Inclisiran on Major Adverse Cardiovascular Events in Participants with Established Cardiovascular Disease (VICTORION-2 PREVENT)
The purpose of this research study is to determine if the study treatment, an FDA approved drug known to be safe and effective in lowering ... -
ZEUS
A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation.